1107 results about "Methylation" patented technology

The invention provides a protein methylation site prediction method fusing quantum and region perception, which comprises the following steps: step 1, acquiring a protein sequence as a data source, and respectively constructing a training set and an independent test set; 2, constructing a multi-modal feature for each protein sequence by adopting a three-way nested scattering network, and fusing the multi-modal features to obtain an optimized fusion feature tensor; and step 3, inputting the optimized fusion feature tensor into a RaQMeNet network model, and performing a methylation site prediction task. The performance indexes of the method are greatly superior to those of the prior art, and the method has higher adaptability, stability and interpretability, can be widely applied to a plurality of bioinformatics and biological medicine related fields such as protein function annotation, disease mechanism research and drug target discovery, and has good application prospects and commercial values.

The invention discloses a synthetic method of a water soluble ultraviolet light absorber BP-9. The method mainly comprises the following process steps: (1) carrying out methylation on the main raw materials of 2, 2', 4, 4'-tetrahydroxyl benzophenone, a transition metal salt catalyst and a mixed solvent which is prepared from dichloroethane and anhydrous ethanol in equal parts by weight to obtain 2, 2'-dihydroxyl-4, 4'-dimethoxyl benzophenone; (2) carrying out sulfonation reaction on the main raw materials of methylate, sulfamic acid and C1-C3 halohydrocarbon to obtain 2, 2'-dihydroxyl-4, 4'-dimethoxyl benzophenone-5, 5'-disulfonic acid; and (3) carrying out neutral reaction on the main raw materials of sulfonated product, inorganic base and ethanol water to finally obtain the BP-9 product. The synthetic method disclosed by the invention is few in reaction step, low in cost, high in product purity and stable in quality, and raw materials are easily available.

The invention provides a methylation detection combined marker based on free DNA (cfDNA) in pulmonary alveolar lavage fluid (BAL) and application of the methylation detection combined marker. The methylation combination marker optimizes methylation detection targets in early screening of lung cancer, reduces detection difficulty and cost, and has high diagnosis accuracy, sensitivity and specificity.

The present disclosure relates to compositions and methods for reducing expression of MYC gene in a cell. In some embodiments, an expression repressor comprises a targeting moiety that binds a MYC promoter, anchor sequence, or super-enhancer. In some embodiments, the expression repressor comprises an effector moiety that represses transcription or methylates DNA. Systems comprising two expression repressors are also disclosed. The compositions can be used, for example, to treat cancers such as HCC.

The application provides a novel DNA methylation marker TAGMe-3 for tumor identification and use thereof. The TAGMe-3 gene sequence region has significant methylation difference between cancer tissues and paracancer tissues. As long as abnormal high methylation state of the TAGMe-3 gene sequence region is detected, the subject is determined to belong to a tumor high-risk population. Moreover, the significant difference of the TAGMe-3 presented between tumor tissues and non-tumor tissues exists in different types of tumors (Pan-cancer) in a wide range.

The invention belongs to the technical field of biological diagnosis, and particularly relates to application of a reagent for detecting DNA methylation of an RPL10 promoter region in preparation of a sow pregnancy diagnosis product. Through methylation high-throughput sequencing of blood DNA of pregnant sows and non-pregnant sows, it is found that the methylation level of a gene promoter region of the ribosomal protein L10 in the early pregnancy stage of the sows is remarkably reduced. The methylation level of the pregnant sow RPL10 is analyzed by using MSP, BSP and qMSP methods, and meanwhile, the ROC curve analysis result also shows that the RPL10 has diagnostic value. The results show that the method for detecting the RPL10 gene in the pig blood sample can be an effective method for diagnosing the early pregnancy of pigs. According to the invention, a pregnancy diagnosis technology based on RPL10 promoter region DNA methylation is preliminarily established, pig pregnancy detection methods are enriched, and a reference is provided for further exploring the DNA methylation level and the regulation mechanism of the pig pregnancy early stage.

Compositions and methods for profiling methylation patterns present on target DNA in solution or affixed to a solid support are disclosed using enzymatic deamination-resistant and optionally also chemically resistant, oligonucleotides and nucleotides.

The invention relates to the field of anti-tumor drugs, and discloses an anti-diffuse large B-cell lymphoma pharmaceutical composition, a preparation method and application thereof, the composition comprises azacitidine and Sanilisoma, the composition can improve the accumulation amount of VDUP1 protein in a cell nucleus through the combination of the methylation effect of DNMT3b on VDUP1 protein and the inhibition of XPO1 activity by Sanilisoma, and the anti-diffuse large B-cell lymphoma pharmaceutical composition can be used for preparing anti-diffuse large B-cell lymphoma. The chemotherapy effect is remarkably improved, the sensitivity of the DLBCL to the Sanisole is remarkably improved, and particularly, the pharmaceutical composition has a remarkable curative effect on R / R DLBCL patients.

The invention discloses an ALS prognosis evaluation system based on UBE2J2 gene methylation and expression level, and relates to the technical field of biomedicine and bioinformatics. Comprising a data acquisition module, a methylation detection module, an expression quantity determination module, a data preprocessing module, a preliminary survival analysis module, a multivariable Cox proportional risk model construction module, an individualized risk index calculation and grouping module and a visualization and clinical application module. By combining UBE2J2 gene methylation and expression quantity analysis, peripheral blood non-invasive detection, standardized experiment and computational analysis process and visual presentation, the method is technically and remarkably superior to the prior art, high accuracy, operability, repeatability and expandability are realized, and the method is suitable for large-scale popularization and application. And the technical defects of single molecular marker, complicated operation, inaccurate prediction and the like in ALS prognosis evaluation in the prior art are overcome.

The invention relates to the technical field of biology, in particular to an MSRE-RPA-CRISPR / Cas12a detection system aiming at a breast cancer methylation site and application of the MSRE-RPA-CRISPR / Cas12a detection system. The MSRE-RPA-CRISPR / Cas12a systems of the four breast cancer methylation sites are constructed and optimized, the visual detection method for the breast cancer methylation sites based on the MSRE-RPA-CRISPR / Cas12a systems is established, the detection method has the advantages of being high in sensitivity, high in specificity and short in detection time, does not depend on large-scale instruments and equipment, the result is visual and visual, and the method is suitable for large-scale popularization and application. The method is suitable for point-of-care testing (POCT).

The present invention relates to a method for diagnosing cancer and predicting cancer types using a methylated cell-free nucleic acid, and more particularly, to a method for diagnosing cancer and predicting cancer types using a method for extracting methylated nucleic acids from a biospecimen, generating vectorized data of nucleic acid fragments based on aligned reads by obtaining sequence information, and then inputting the data into a trained artificial intelligence model so as to analyze a calculated value. The method for diagnosing cancer and predicting cancer types using methylated cell-free nucleic acids according to the present invention is useful because it generates vectorized data and analyzes it using an AI algorithm, compared to methods that use a conventional step of determining the amount of chromosomes based on the read count or detection methods that use the concept of distance between aligned reads to utilize values related to reads as one by one structured values, so that a similar effect can be achieved even if the read coverage is low.

The invention belongs to the technical field of gene engineering, and relates to an esophageal squamous cell carcinoma diagnostic kit based on a peripheral blood mononuclear cell methylation marker and application. The kit comprises a primer pair which is used for detecting the methylation of a cg05914150 site, a cg06769875 site, a cg07475126 site, a cg08433285 site, a cg10038907 site, a cg17968322 site, a cg19572487 site, a cg20184330 site, a cg22741248 site and a cg22823192 site. According to the detection kit provided by the invention, the type of a detected sample is peripheral blood, the sample is relatively easy to obtain and non-invasive, and the patient compliance is relatively good. Abnormal methylation changes mostly exist in the early progression process of tumors, early diagnosis of ESCC can be achieved through the methylation detection method provided by the invention, and the five-year survival rate of ESCC patients is effectively increased.

The invention discloses a preparation method of L-5 methyltetrahydrofolic acid based on an MOFs catalyst, and high-selectivity hydrogenation and methylation of folic acid are realized under mild conditions by designing MOFs material loaded noble metal nanoparticles with a chiral confinement effect. The method does not need an optical resolution step, and the ee value of the product is gt; and the catalyst can be recycled, so that the method is suitable for industrial production.

The invention relates to the field of analysis and detection, and discloses a method for detecting multiple chelating agents in daily chemical products, which comprises the following steps: methylating a to-be-detected sample by using a diazomethane methylation reagent to obtain a to-be-detected solution; carrying out liquid chromatography-mass spectrometry detection on the to-be-detected liquid by adopting a specific elution program to obtain a chromatogram; and performing qualitative and / or quantitative analysis on the chelating agent in the to-be-detected sample according to the chromatogram. By adopting the detection method disclosed by the invention, efficient detection of various chelating agents (including DTPA, DTPMP, EDTMPA, HDTEPA, EGTA, HEDP, EDTA, NTA, GLDA, PBTC, MGDA, IDS, HEEDTA, HPAA, DTPA-OH, CA and ATMP) can be realized, meanwhile, interference of other components in daily chemical products on detection can be avoided, and relatively high detection sensitivity and accuracy of the chelating agents can be realized.

The invention relates to the technical field of biological detection, and discloses a reagent composition and a kit for detecting cervical cancer and precancerous lesions of cervical cancer and application of the reagent composition and the kit. The reagent composition provided by the invention is used for detecting the methylation degree of a specific marker gene, and the detection sensitivity and specificity of cervical cancer and high-grade cervical cancer precancerous lesions are at a relatively high level. When the reagent composition is used for screening cervical cancer and precancerous lesions of HPV positive people, compared with conventional cytological detection, the colposcope referral rate is greatly reduced, meanwhile, the detection times for definite diagnosis of high-grade cervical lesions or cervical cancer are reduced, and the waste of medical resources and the examination burden of patients are reduced.

The present application relates to a kind of purine derivatives as the use of NSD2 and NSD3 inhibitor, the structural formula of the derivative is as shown in formula (I) or formula (II).The compound shows good NSD2, NSD3 inhibitory activity, can effectively reduce the methylation level of H3K36 in cell, and cause the reduction of cell proliferation activity of NSD2, NSD3 high expression tumor cell strain.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to N-methylation modified cyclopeptide and application thereof. On the basis of a GluA2-3Y polypeptide sequence, chemical modification and transformation of amido bond N-methylation and head-tail cyclization are carried out, the N-methylation modified cyclopeptide with stable metabolism and good permeability is obtained, and the endocytosis of a GluA2AMPA receptor is blocked to protect nerve cells, so that the GluA2AMPA receptor can be effectively inhibited, and the GluA2AMPA receptor can be effectively inhibited. The invention also provides application of the cyclic peptide in preparation of drugs for treating cerebral arterial thrombosis.

The invention provides a methylation marker for risk assessment of prostatic cancer and application of the methylation marker, and relates to the technical field of molecular biomedicine. The invention provides a methylation marker for early non-invasive identification of prostatic cancer and a combination thereof, and a new marker group related to identification of prostatic cancer is identified based on methylation sequencing data analysis of measured tissue interstitial fluid and urine EV DNA samples of prostatic cancer patients and cancer-free patients. The marker group can effectively distinguish benign and malignant prostate cancer or distinguish inert prostate cancer and highly invasive prostate cancer, a new biomarker is provided for prostate cancer identification, and compared with the previously reported and used technical means, the marker group can more sensitively detect the methylation change of related genes of prostate cancer, and has a good application prospect. More favorable evidence is provided for early diagnosis of the prostate cancer, and a new method is provided for early diagnosis of the prostate cancer.

A kit includes a flow cell, an extension mix, and an enzymatic methylation conversion mix. The flow cell includes a substrate having depressions separated by interstitial regions; first and second primers immobilized within each of the depressions; and first and second transposome complexes immobilized within each of the depressions and / or over each of the interstitial regions. The kit may be used for on-flow cell library preparation and methylation detection.

The invention discloses a colorectal cancer Septin9 gene methylation detection kit based on a graded anchoring probe, and belongs to the technical field of molecular diagnosis. The graded anchoring probe is composed of a specific capture probe (F1), a precise anchoring probe (R1), a synergistic blocking probe (F2 / R2) and a short chain complementary sequence (S1) which are Septin9 methylation specific probes and can be fixed in a conical pore channel of a nuclear track membrane in a graded manner to form a capture-anchoring-blocking functional chain; during application, a general accumulation body is formed by combining with a Septin9 methylation target, a nuclear track membrane pore channel is blocked, current drop is caused, and detection is realized. Through cooperation of the probe, the nuclear track membrane and the electrochemistry, the problems of insufficient sensitivity, poor stability and poor specificity of traditional detection are solved, and the kit is suitable for ultra-early diagnosis of colorectal cancer.

The present description provides a cancer assay panel for targeted detection of cancer-specific methylation patterns. Further provided herein includes methods of designing, making, and using the cancer assay panel for diagnosis of cancer.

The invention discloses a recombinant bacillus paralicheniformis and an application of the recombinant bacillus paralicheniformis in production of betaine. According to the invention, bacillus paralicheniformis Bp1 with heavy metal cadmium resistance is used as a chassis strain, and an de novo synthesis pathway which takes glucose as a substrate and synthesizes glycine betaine through glycolysis, glyoxylic acid pathway and glycine methylation pathway in sequence is established in the bacillus paralicheniformis, so that the survival rate of the glycine betaine in cadmium-polluted soil is increased; the effects of the microbial soil treating agent and the microbial fertilizer are improved, so that the growth of the plant-black nightshade with an enrichment effect on cadmium and the absorption of the black nightshade on the cadmium in the polluted soil are promoted.

The embodiments of the present description provide a method for generating a cancer risk level prediction model. The method comprises: using a training set and labels to train each of an initial first, second, third, and fourth prediction model, so as to obtain a trained first, second, third, and fourth prediction model, wherein the training set comprises methylation data of a cancer-related methylation site of each sample among training samples, and the labels are cancer risk levels of the samples; using each of the trained first, second, third, and fourth prediction models to make a prediction with respect to samples in a prediction set, so as to obtain a prediction result from each of the four prediction models, wherein the prediction results of the third and fourth prediction models are input into a fifth prediction model, so as to obtain a prediction result from the fifth prediction model; and determining whether each prediction result meets a preset condition, and if so, then training is complete; and if not, performing further iteration until each prediction result meets the preset condition.

The invention relates to the technical field of biological detection, and discloses a reagent composition for detecting urothelial carcinoma, a kit and application. The composition provided by the invention is used for detecting the methylation state of a specific target sequence in a characteristic gene of the urinary tract epithelial cancer, and the detection sensitivity and specificity of the urinary tract epithelial cancer are at a relatively high level. The composition provided by the invention can be used for noninvasive urinary tract epithelium cancer screening, and when the composition is used for urinary tract epithelium cancer screening, compared with conventional urine cytology examination and iconography examination, the detection sensitivity is greatly improved, the early screening accuracy of urinary tract epithelium cancer is improved, and the misdiagnosis rate and the missed diagnosis rate are greatly reduced.

Provided are a method and apparatus for training a prediction model, and an electronic device, a computer-readable storage medium and a computer program product. The method is applied to the electronic device, and comprises: pre-training a first prediction model on the basis of a plurality of first-sample whole-genome sequences so as to obtain a second prediction model; extracting target dinucleotide sites from a plurality of dinucleotide sites in each of the first-sample whole-genome sequences, and using, as second-sample whole-genome sequences, sequences within a preconfigured window range containing the target dinucleotide sites; annotating the actual methylation state for the target dinucleotide sites in each of the second-sample whole-genome sequences; and training the second prediction model on the basis of each of the annotated second-sample whole-genome sequences so as to obtain a trained third prediction model, wherein the third prediction model is used for predicting the methylation state of dinucleotide sites in whole-genome sequences to be detected.

Provided herein are methods of identifying methylation status of a nucleic acid, e.g., RNA in a biological sample. Also provided herein are methods for identifying the methylation status of RNA in a biological sample with spatial technology to identify the location of a methylated RNA in the biological sample.

The invention relates to application of PWWP2B as a target spot in preparation of leukemia treatment drugs, and belongs to the technical field of biological medicines. In order to solve the problem that a traditional AML treatment target is lack of tumor specificity and is difficult to meet clinical requirements, the invention provides application of PWWP2B as a target in preparation of leukemia treatment drugs. The invention proves that PWWP2B is highly expressed in acute myelogenous leukemia cells, and the PWWP2B as a molecular marker can accurately distinguish acute myelogenous leukemia from normal healthy people or non-leukemia patients. In-vivo and in-vitro experiments prove that by knocking out PWWP2B, proliferation and clone formation of acute myelogenous leukemia cells can be remarkably inhibited, differentiation and apoptosis of the acute myelogenous leukemia cells are promoted, and activity of leukemia cells in a patient body is inhibited. The invention discloses the new application of the small molecule compound EZM0414 in treating acute myelogenous leukemia for the first time, and the synergistic interaction of the small molecule compound EZM0414 and a methylase inhibitor can be realized.

The present description provides a cancer assay panel for targeted detection of cancer-specific methylation patterns. Further provided herein are methods of designing, making, and using the cancer assay panel for the diagnosis of cancer.

The invention relates to the technical field of small molecule polypeptides and leukemia treatment drugs, in particular to an EMBOW derived peptide targeting WDR5-MLL1 protein interaction and application of the EMBOW derived peptide, the amino acid sequence of the EMBOW derived peptide is shown as SEQ ID NO: 1, the N end of the EMBOW derived peptide is subjected to acetylation modification, and the C end of the EMBOW derived peptide is subjected to protective modification. The EMBOW derived peptide can target WDR5, inhibit protein interaction between WDR5-MLL1 and inhibit the methylation level of histone H3K4, and can be used for preparing a medicine for treating MLL1 gene rearrangement type leukemia.

The invention belongs to the technical field of bioinformatics and deep learning, and particularly relates to a DNA methylation site prediction method, system and device and an electronic medium, and the method comprises the following steps: respectively coding single bases in a DNA sequence into four molecular fingerprints, and constructing each base into a molecular map structure; performing high-order feature extraction on the four molecular fingerprints through a multi-layer perceptron to generate molecular fingerprint features; modeling the molecular graph structure by adopting a multi-head graph attention network, calculating and normalizing attention scores among nodes, carrying out weighted summation on neighbor node features, and carrying out multi-head attention fusion to generate molecular graph features; splicing the molecular fingerprint features and molecular map features, and inputting the spliced molecular fingerprint features and molecular map features into a deep convolution gated channel attention module to generate fused features; and obtaining a prediction probability of the fused features, and judging whether the features are methylation sites or not according to the prediction probability. According to the invention, the identification capability of methylation sites can be improved.